Form 4: Pershing Edward reports purchase transactions in PVCT

Rhea-AI Filing Summary

Pershing Edward reported open-market purchase transactions in a Form 4 filing for PVCT. The filing lists transactions totaling 34,940 shares at a weighted average price of $2.86 per share. Following the reported transactions, holdings were 2,613,807 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pershing Edward

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TN 37929

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series D-1 Convertible Preferred Stock(1)	(2)	02/09/2026		P		34,940		02/09/2026	(3)	Common Stock	349,400	$2.862	2,613,807	D

Explanation of Responses:

1. The Reporting Person acquired 34,940 shares of Series D-1 Preferred Stock in a private transaction.

2. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

3. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

	/s/ Edward Pershing	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PVCT CEO Edward Pershing report on this Form 4?

Edward Pershing reported buying 34,940 shares of Series D-1 Convertible Preferred Stock. The shares were acquired in a private transaction on February 9, 2026, at $2.862 per share, increasing his directly held derivative securities to 2,613,807 after the transaction.

At what price did PVCT’s CEO acquire the Series D-1 Convertible Preferred Stock?

The CEO acquired the Series D-1 Convertible Preferred Stock at $2.862 per share. The filing shows a single transaction on February 9, 2026, covering 34,940 preferred shares, all purchased at this price in a private transaction, as noted in the explanatory footnotes.

How many PVCT derivative securities does Edward Pershing own after this transaction?

After the reported transaction, Edward Pershing beneficially owns 2,613,807 derivative securities. This total reflects his holdings of Series D-1 Convertible Preferred Stock following the February 9, 2026 purchase of 34,940 additional shares disclosed in the insider trading report.

How is PVCT’s Series D-1 Convertible Preferred Stock convertible into common stock?

Each share of PVCT’s Series D-1 Convertible Preferred Stock converts into 10 shares of common stock. This fixed conversion rate is specified in the filing’s footnotes, linking each preferred share directly to ten common shares with a par value of $0.001 per share.

When will PVCT’s Series D-1 Convertible Preferred Stock automatically convert into common stock?

The Series D-1 Convertible Preferred Stock will automatically convert into common stock on December 31, 2028. It can also be converted earlier according to the terms in the Certificate of Designation, giving a defined end date for automatic conversion into common shares.

What is Edward Pershing’s role at Provectus Biopharmaceuticals (PVCT)?

Edward Pershing serves as both a director and the CEO of Provectus Biopharmaceuticals, Inc. The Form 4 identifies him as an officer with the title CEO and as a director, while indicating he is not classified as a ten percent owner in this filing.